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haematologist, included the following domains: reliance on
transfusions/health care providers; arranging life around medical
appointments; fatigue limiting routine physical activities; disease
interference with social and family life; worry about the future
due to health condition; discomfort; reliance on support for self
care and routine activities; feelings of being a burden to family;
and feeling sad, hopeless, and helpless. Face-to-face interviews
used the Feeling Thermometer VAS and the TTO method to
value the HS on a 0 (dead) to 1 (perfect health) scale. Socio-
demographic, clinical, and quality-of-life (EQ-5D) characteristics
were surveyed. RESULTS: The mean age was 67 y (range:
29–83); 45% male, 70% retired; 40% had secondary/high school
education, or higher (32%), and 79% lived with family, a partner
or spouse, or friends. The mean time from MDS diagnosis was 5
years (range: 1–23). Most patients (87%) received previous
transfusions and 49% had received a transfusion in the last 3
months. Mean utility score was 0.78; patients reported at least
some problem with mobility (45%), usual activities (40%), pain/
discomfort (47%), and anxiety/depression (34%). Few patients
had difﬁculty understanding the VAS (n = 3) and TTO (n = 4)
exercises. Utility scores for TI were higher than for RT (0.84 vs.
0.77; p = 0.06) or TD (0.84 vs. 0.60; p < 0.001). Three patients
rated TD worse than dead. Corresponding VAS scale scores were
78 vs. 56; (p < 0.001), and 78 vs. 31 (p < 0.001), respectively.
CONCLUSION: Patients value TI, suggesting an important role
for new treatments aiming to achieve greater TI in MDS.
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OBJECTIVES: Chronic iron overload due to frequent blood
transfusions is a condition affecting patients with a wide range of
disorders including beta-thalassaemia, sickle cell disease and
myelodysplastic syndromes. A UK community based utility study
was conducted to value preferences for iron chelation therapy
(ICT) administered via two different modes of administration:
once daily oral administration (deferasirox) and slow subcutane-
ous infusion for 8–12 hours per day, 5–7 days/week (current
standard treatment desferrioxamine). METHODS: Time trade
off (TTO) methods were used to value health states for oral and
subcutaneous modes of ICT administration. An anchor descrip-
tion for the reference condition, beta-thalassaemia, was incorpo-
rated within each health state. The descriptions were validated by
5 UK clinicians. Neither health state made reference to the asso-
ciated drug name. Mean utilities were estimated and 95% con-
ﬁdence intervals calculated using bootstrapping sampling and
estimation. The Wilcoxon Signed-Rank Test was used to test
signiﬁcant differences between the health state mean utility
values. RESULTS: A representative cross sectional sample of 120
respondents from the UK population participated in the TTO
exercise. Analysis was performed for 115 respondents (5
responses were excluded due to lack of understanding of the
exercise). 54% were female, 76% aged 21–60 years. Mean utility
for the oral ICT health state was 0.84 (SD: 0.17) compared to
0.66 (SD: 0.21) for the subcutaneous infusion ICT health state.
There was a mean difference of 0.17 (95% CI: 0.147, 0.214) in
utility values between the health states (p < 0.0001). The utility
results are consistent with those from a similarly designed Aus-
tralian study. CONCLUSION: From a societal perspective the
utility beneﬁt associated with once daily oral ICT for chronic
iron overload is signiﬁcantly greater relative to current standard
subcutaneous treatment. This data can be used in cost-utility
analyses comparing oral Deferasirox and current standard care
desferrioxamine.
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OBJECTIVES: The aim of this study was to provide insights into
the experiences, behavior and attitudes of patients towards
controlled ovarian stimulation (COS). METHODS: A cross-
sectional explorative study involving semi-structured in-depth
interviews, including a laddering technique (means–end relation
theory) to link treatment characteristics to emotional drivers. A
total of 190 women (age 25–40) in France, Germany, Italy,
Japan, Spain, Turkey, UK and USA who completed an IVF cycle
in the last 6 months were randomly allocated via general popu-
lation databases. RESULTS: When asked about their experiences
during the COS phase 31% of patients mentioned that COS
limited their daily activities because they wanted to be home at
speciﬁc times for the injections and 19% described the schedule
as stressful or emotionally demanding. Most mentioned incon-
veniences regarding injections were timing of injections, injection
site pain and the hassle with syringes and vials. In spite of
education and training on injections, 59% of women were con-
cerned about incorrect injections. In total 45% of women expe-
rienced difﬁculties, like injecting at the wrong time, incorrect
dosing, hitting a vessel or fear of self-injection. Having realized
they had made a mistake, 68% felt worried or stressed about it
and 13% were anxious that it would have a negative impact on
treatment outcome. When asked women said that daily injection
regimens could be improved by pen or oral administration, by
pre-mixed ready-for-use methods and by reducing the number of
injections. This would reduce the worries and stress associated
with COS and 40% of subjects stated to believe that this would
improve their emotional well-being and increase their chance of
a baby. CONCLUSION: COS has serious emotional and psycho-
logical impact on patients undergoing IVF. According to women
simple and short treatment regimen with less concern about
correct administration will improve their emotional well-being
during COS.
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OBJECTIVES: The management of hemophilia when patients
develop inhibitors is particularly complex and costly. Although
the advances of modern technologies, no agreement still exists on
how to optimally treat these patients. Treatment of haemophilia
is result of interactions between patients, physicians, pharmacists
and budget holders, each carrying their own set of preferences.
This study was conducted to evaluate preferences toward pos-
sible coagulation factor concentrates used in patients with inhibi-
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tors from a sample of patients (or caregivers of pediatric
patients), physicians specialist in hemophilia care, pharmacists
with experience in storing/delivering coagulation factor concen-
trates. METHODS: A Discrete Choice Experiment was con-
ducted, by describing possible products with 7 attributes selected
from a previous pilot study: “viral safety”, “risk of anamnestic
response”, “possibility of undergoing major surgery”, “fre-
quency of infusions in prophylaxis”, “number of injections to
stop bleeding”, “time to stop bleeding”, “time to pain recovery”.
Cost, expressed as increase of health care taxes, was added to
estimate willingness to pay towards these attributes. The respon-
dents were asked to choose among 16 pair-wise choice sets.
A random-effect logit model was used to analyse the data.
RESULTS: Thirty-seven patients or proxies (their caregivers), 39
physicians, 25 pharmacists were interviewed. All the patients
had severe hemophilia A, historical median (min-max) peak
titre = 164 (5–16,400) BU/mL. Among all the respondents, the
hypothesized direction of preferences was conﬁrmed (e.g. lower
risk of infections was preferred than higher risk) and the impor-
tance of preferences was statistically signiﬁcant: p-values < 0.01
for every attribute. The 3 subgroups anyway reported different
preferences in some attributes. CONCLUSION: this study
revealed patients/caregivers’, physicians’ and pharmacists’ pref-
erences towards the products used to treat hemophilic patients
with inhibitors. Understanding the preferences from different
perspectives can be useful to optimize the beneﬁts deriving
from the decisions on treatments for hemophilic patients with
inhibitors.
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OBJECTIVES: Using a sample of adult Medicaid enrollees, this
study examined physician prescribing practices associated with
MDD. We compared behavioral, physical, and pharmacy service
use and cost outcomes associated with different prescribing pat-
terns. Speciﬁcally, we examined three cohorts of enrollees: 1)
persons with MDD; 2) persons with diabetic peripheral neuropa-
thy (DPN); and 3) persons with MDD and DPN. We compared
outcomes for patients prescribed Duloxetine to those prescribed
other antidepressant medications. METHODS: The sample
included 32,663 patients diagnosed with MDD and or DPN who
were enrolled in the Florida Medicaid Program during FY2003-
05. Three years of claims data were used to compare demograph-
ics, diagnostic characteristics, antidepressant medication use, and
service expenditures six months prior to and one year after the
index prescription event. RESULTS: Among persons diagnosed
with MDD, the majority (84.5%) received SSRIs alone or in
combination with other antidepressants, 29.2% received SNRIs
alone or in combination, and 15.3% received TCAs alone or in
combination. A large majority (86.5%) also received prescription
pain medication. Of these patients, more than half received pre-
scription narcotics on a daily basis. Predictors of increased
service use and cost following initiation of antidepressant treat-
ment included older age, female gender, and pre-index prescrip-
tion costs. Results indicated physical health care costs increased
after any switches in antidepressants. However, behavioral health
costs decreased for all treated patients over time, most dramati-
cally for inpatient service expenditures. Patients receiving Dulox-
etine reduced their narcotic use following treatment, while
patients receiving other antidepressant medications maintained
or increased narcotics use. CONCLUSION: Current data indi-
cates many patients with MDD also experience chronic pain
conditions requiring narcotics or other pain medications. SNRI’s
may facilitate a reduction in pain medication use and therefore
might be the antidepressant of choice for patients with co-morbid
MDD and chronic pain.
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OBJECTIVES: To summarize published data on the burden of
GAD to assist decision makers in Germany. METHODS: A
review of English-language studies on the human, health care and
economic burden of GAD in Germany. Studies were identiﬁed
using electronic databases (MEDLINE/EMBASE) and references
from published articles. RESULTS: National prevalence esti-
mates indicate that GAD affected 1.5% of adults in the general
population in the past 12-months and 5.3% of primary care
patients in the past 1-month. GAD commonly co-occurred with
other mental disorders, especially major depression (MD).
Impairments observed in people with GAD were not merely due
to comorbidity. People with pure GAD (GAD without comorbid
MD) reported high levels of occupational impairment that were
similar or greater in magnitude compared to that of people with
pure MD (MD without comorbid GAD). People with pure GAD
also reported more severe mental and physical health status
impairments compared to people with pure MD. High use of
health care resources among GAD primary care patients was
not solely due to comorbidity. The proportion of comorbid
GAD/MD cases was smaller than that of pure GAD cases
(4-week point prevalence estimates of 1.6% and 3.8%, respec-
tively). A greater proportion of primary care patients with
comorbid GAD/MD (43%) and pure GAD (42%) reported high
use of specialists (2 + visits/year) than pure MD patients (36%).
A greater proportion of GAD patients sought help for somatic
illness/complaints (48%), pain (35%) and sleep problems (33%)
than for anxiety (13%). GAD was considerably less likely to be
recognized and treated than MD. The per-patient cost of GAD
(€1628 in 2004) was higher than that of any other anxiety
disorder, owing to lost work and health care utilization. CON-
CLUSION: German data show that GAD is a distinct and bur-
densome disorder. Improved recognition and treatment of GAD
should be an important public health priority.
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OBJECTIVES: To present the outcomes associated with olanza-
pine treatment of schizophrenia patients participating in the
Olanzapine Post Marketing Surveillance in Japan (OPMS-J), and
to compare the maintenance rate of olanzapine in the OPMS-J
with that of typical and atypical antipsychotic medication in
the Schizophrenia Outpatient Health Outcomes (SOHO) study.
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